ウゴービ皮下注
非アルコール性脂肪肝炎（NASH）

2.7.4.7 付録
1.医薬品への曝露及びベースライン特性

ノボ ノルディスク ファーマ株式会社

Table of contents

Page

7.1.1 Total exposure - phase 2 and phase 3 trials - on-treatment - safety analysis set - trials 4553 (interim), 4296 and 4492 3
7.1.2 Exposure by month - on treatment - safety analysis set (interim) - trial 4553 4
7.1.3 Exposure by month - on treatment - safety analysis set - trial 4296 5
7.1.4 Exposure by month - on treatment - safety analysis set - trial 4492 6
7.1.5 Exposure by subgroup - on-treatment - safety analysis set (interim) - trial 4553 7

7.1 Exposure to the drug and baseline characteristics

7.1.1 Total exposure - phase 2 and phase 3 trials - on-treatment - safety analysis set - trials 4553 (interim), 4296 and 4492

	Sema 0.1 mg OD		Sema 0.2 mg OD		Sema 0.4 mg OD		Sema 2.4 mg		Total Sema		Placebo		Total	
	N	PYE	N	PYE	N	PYE	N	PYE	N	PYE	N	PYE	N	PYE
Total exposed	80	115.4	78	105.8	81	114.2	847	1381.2	1086	1716.6	499	765.3	1585	4198.5
Trial														
NN9931-4296 (phase 2)	80	115.4	78	105.8	81	114.2	0	0.0	239	335.4	80	113.7	319	784.4
NN9931-4492 (phase 2)	0	0.0	0	0.0	0	0.0	47	46.0	47	46.0	24	24.6	71	116.6
NN9931-4553 (phase 3)	0	0.0	0	0.0	0	0.0	800	1335.3	800	1335.3	395	627.0	1195	3297.5

N: Number of subjects, OD: Once daily, OW: Once weekly, PYE: Person-years of exposure.

7.1.2 Exposure by month - on treatment - safety analysis set (interim) - trial 4553

	Sema 2.4 mg		Placebo		Total	
	N	(%)	N	(%)	N	(%)
Number of subjects	800		395		1195	
Observation time (years)	1335		627.0		1962	
Duration of exposure (months)						
>=0	800	(100.0)	395	(100.0)	1195	(100.0)
>=1	774	(96.8)	387	(98.0)	1161	(97.2)
>=2	756	(94.5)	376	(95.2)	1132	(94.7)
>=3	728	(91.0)	360	(91.1)	1088	(91.0)
>=4	693	(86.6)	345	(87.3)	1038	(86.9)
>=5	688	(86.0)	344	(87.1)	1032	(86.4)
>=6	643	(80.4)	316	(80.0)	959	(80.3)
>=7	635	(79.4)	312	(79.0)	947	(79.2)
>=8	634	(79.3)	306	(77.5)	940	(78.7)
>=9	594	(74.3)	286	(72.4)	880	(73.6)
>=10	589	(73.6)	280	(70.9)	869	(72.7)
>=11	576	(72.0)	269	(68.1)	845	(70.7)
>=12	542	(67.8)	252	(63.8)	794	(66.4)
>=13	540	(67.5)	249	(63.0)	789	(66.0)
>=14	498	(62.3)	233	(59.0)	731	(61.2)
>=15	493	(61.6)	229	(58.0)	722	(60.4)
>=16	491	(61.4)	226	(57.2)	717	(60.0)
>=17	467	(58.4)	213	(53.9)	680	(56.9)
>=18	453	(56.6)	202	(51.1)	655	(54.8)
>=19	444	(55.5)	199	(50.4)	643	(53.8)
>=20	407	(50.9)	188	(47.6)	595	(49.8)
>=21	406	(50.8)	187	(47.3)	593	(49.6)
>=22	398	(49.8)	181	(45.8)	579	(48.5)
>=23	371	(46.4)	164	(41.5)	535	(44.8)
>=24	369	(46.1)	162	(41.0)	531	(44.4)
>=25	336	(42.0)	147	(37.2)	483	(40.4)
>=26	329	(41.1)	140	(35.4)	469	(39.2)
>=27	329	(41.1)	140	(35.4)	469	(39.2)
>=28	259	(32.4)	107	(27.1)	366	(30.6)
>=29	254	(31.8)	105	(26.6)	359	(30.0)
>=30	252	(31.5)	104	(26.3)	356	(29.8)
>=31	166	(20.8)	73	(18.5)	239	(20.0)
>=32	165	(20.6)	71	(18.0)	236	(19.7)
>=33	143	(17.9)	64	(16.2)	207	(17.3)
>=34	70	(8.8)	33	(8.4)	103	(8.6)
>=35	68	(8.5)	32	(8.1)	100	(8.4)
>=36	28	(3.5)	16	(4.1)	44	(3.7)
>=37	14	(1.8)	8	(2.0)	22	(1.8)
>=38	14	(1.8)	8	(2.0)	22	(1.8)
>=39	[redacted]					
>=40	0	(0.0)	0	(0.0)	0	(0.0)

%: Percentage of subjects, N: Number of subjects, PYE: Person-years of exposure.

7.1.3 Exposure by month - on treatment - safety analysis set - trial 4296

	Sema 0.1 mg OD		Sema 0.2 mg OD		Sema 0.4 mg OD		Placebo		Total	
	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)
Number of subjects	80		78		81		80		319	
Observation time (years)	115.4		105.8		114.2		113.7		449.0	
Duration of exposure (months)										
>=0	80	(100.0)	78	(100.0)	81	(100.0)	80	(100.0)	319	(100.0)
>=1	80	(100.0)	78	(100.0)	81	(100.0)	80	(100.0)	319	(100.0)
>=2	80	(100.0)	78	(100.0)	81	(100.0)	80	(100.0)	319	(100.0)
>=3	78	(97.5)	76	(97.4)	80	(98.8)	79	(98.8)	313	(98.1)
>=4	77	(96.3)	73	(93.6)	78	(96.3)	78	(97.5)	306	(95.9)
>=5	77	(96.3)	72	(92.3)	77	(95.1)	78	(97.5)	304	(95.3)
>=6	76	(95.0)	70	(89.7)	75	(92.6)	78	(97.5)	299	(93.7)
>=7	76	(95.0)	70	(89.7)	75	(92.6)	75	(93.8)	296	(92.8)
>=8	76	(95.0)	69	(88.5)	75	(92.6)	75	(93.8)	295	(92.5)
>=9	76	(95.0)	68	(87.2)	75	(92.6)	75	(93.8)	294	(92.2)
>=10	76	(95.0)	68	(87.2)	74	(91.4)	75	(93.8)	293	(91.8)
>=11	76	(95.0)	68	(87.2)	74	(91.4)	75	(93.8)	293	(91.8)
>=12	76	(95.0)	68	(87.2)	74	(91.4)	75	(93.8)	293	(91.8)
>=13	76	(95.0)	67	(85.9)	74	(91.4)	73	(91.3)	290	(90.9)
>=14	76	(95.0)	67	(85.9)	74	(91.4)	73	(91.3)	290	(90.9)
>=15	76	(95.0)	67	(85.9)	74	(91.4)	73	(91.3)	290	(90.9)
>=16	76	(95.0)	67	(85.9)	72	(88.9)	71	(88.8)	286	(89.7)
>=17	75	(93.8)	67	(85.9)	72	(88.9)	71	(88.8)	285	(89.3)
>=18	52	(65.0)	48	(61.5)	49	(60.5)	47	(58.8)	196	(61.4)
>=19	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)

%: Percentage of subjects, N: Number of subjects, OD: Once daily, PYE: Person-years of exposure.

7.1.4 Exposure by month - on treatment - safety analysis set - trial 4492

	Sema 2.4 mg		Placebo		Total	
	N	(%)	N	(%)	N	(%)
Number of subjects	47		24		71	
Observation time (years)	46.0		24.6		70.6	
Duration of exposure (months)						
>=0	47	(100.0)	24	(100.0)	71	(100.0)
>=1	47	(100.0)	24	(100.0)	71	(100.0)
>=2	47	(100.0)	24	(100.0)	71	(100.0)
>=3	46	(97.9)	24	(100.0)	70	(98.6)
>=4	46	(97.9)	24	(100.0)	70	(98.6)
>=5	46	(97.9)	24	(100.0)	70	(98.6)
>=6	46	(97.9)	24	(100.0)	70	(98.6)
>=7	43	(91.5)	23	(95.8)	66	(93.0)
>=8	42	(89.4)	23	(95.8)	65	(91.5)
>=9	41	(87.2)	23	(95.8)	64	(90.1)
>=10	41	(87.2)	23	(95.8)	64	(90.1)
>=11	40	(85.1)	23	(95.8)	63	(88.7)
>=12	40	(85.1)	22	(91.7)	62	(87.3)
>=13	2	(4.3)	2	(8.3)	4	(5.6)
>=14	0	(0.0)	0	(0.0)	0	(0.0)

%: Percentage of subjects, N: Number of subjects, OD: Once daily, PYE: Person-years of exposure.

nn9931/nn9931-submission-level1/safety_l1_20250130_er
30JAN2025:09:37:15 - texpmonth.sas/texpmonth4492.txt

7.1.5 Exposure by subgroup - on-treatment - safety analysis set (interim) - trial 4553

	Sema 2.4 mg		Placebo		Total	
	N	PYE	N	PYE	N	PYE
Number of subjects	800	1335.3	395	627.0	1195	1962.3
Age at baseline						
N	800	1335.3	395	627.0	1195	1962.3
< 45	120	200.5	83	122.8	203	323.3
45-65<	470	787.1	213	355.3	683	1142.4
>= 65	210	347.6	99	149.0	309	496.6
Sex						
N	800	1335.3	395	627.0	1195	1962.3
Female	451	763.6	215	342.6	666	1106.2
Male	349	571.7	180	284.4	529	856.1
Race						
N	800	1335.3	395	627.0	1195	1962.3
AIAN	6	6.0	1	0.5	7	6.5
Asian	215	360.7	111	187.3	326	548.0
Black or African American	8	10.0	3	5.8	11	15.7
White	529	891.9	261	401.6	790	1293.5
Other	34	49.9	17	28.7	51	78.5
Missing	8	16.8	2	3.2	10	20.0
Ethnicity						
N	800	1335.3	395	627.0	1195	1962.3
Hispanic or Latino	144	226.3	76	122.9	220	349.2
Not Hispanic or Latino	626	1059.8	309	492.8	935	1552.7
Not Reported	25	40.4	8	8.0	33	48.4
Missing	5	8.8	2	3.2	7	12.0
Diabetes status at baseline						
N	800	1335.3	395	627.0	1195	1962.3
T2D	446	749.3	222	355.1	668	1104.3
NT2D	354	586.0	173	272.0	527	858.0
Glycaemic status at baseline						
N	800	1335.3	395	627.0	1195	1962.3
Normo-glycaemia	143	253.1	70	117.9	213	371.0
Pre-diabetes	657	1082.2	324	506.1	981	1588.3
Missing	[redacted]					
Fibrosis stage at baseline						
N	800	1335.3	395	627.0	1195	1962.3
F2	174	411.0	82	176.2	256	587.2
F3	626	924.2	313	450.8	939	1375.1
Body mass index at baseline						
N	800	1335.3	395	627.0	1195	1962.3
<27	113	174.0	44	77.7	157	251.7
27-30<	115	188.3	53	81.3	168	269.6
30-35<	249	429.3	114	179.1	363	608.4
>=35	323	543.6	183	286.0	506	829.6
Missing	[redacted]					

AIAN: American Indian or Alaskan Native, ALT: Alanine Aminotransferase, AST: Aspartate Aminotransferase, DV3396: Single-dose pen-injector, N: Number of subjects, NT2D: Subjects without a type 2 diabetes diagnosis at baseline, PDS290: Multi-dose pen-injector, PYE: Person-years of exposure, RI: Renal impairment, T2D: Type 2 diabetes, ULN: Upper limit of normal range. ALP: Alkaline Phosphatase. Lean NASH: Body mass index <25 for non-Asian subjects and body mass index <23 for Asian subjects. Renal impairment is classified as Normal (eGFR >=90 mL/min/1.73 m2), Mild (eGFR >=60 to <90 mL/min/1.73 m2), Moderate (eGFR >= 30 to <60 mL/min/1.73 m2), Severe (eGFR >= 15 to <30 mL/min/1.73 m2).

Exposure by subgroup - on-treatment - safety analysis set (interim) - trial 4553

	Sema 2.4 mg		Placebo		Total	
	N	PYE	N	PYE	N	PYE
AST at baseline						
N	800	1335.3	395	627.0	1195	1962.3
<= ULN	201	322.2	89	156.0	290	478.2
> ULN to <=3x ULN	542	921.2	273	425.0	815	1346.2
>3x ULN	57	91.8	33	46.0	90	137.8
ALT at baseline						
N	800	1335.3	395	627.0	1195	1962.3
<= ULN	376	613.7	182	289.6	558	903.3
> ULN to <=3x ULN	398	677.4	197	310.6	595	988.0
>3x ULN	26	44.2	16	26.8	42	71.0
ALP at baseline						
N	800	1335.3	395	627.0	1195	1962.3
<= ULN	773	1287.9	377	599.8	1150	1887.7
> ULN	27	47.3	18	27.3	45	74.6
Renal function at baseline						
N	800	1335.3	395	627.0	1195	1962.3
Normal	556	936.8	284	455.0	840	1391.8
Mild RI	204	346.7	103	159.6	307	506.2
Moderate RI	38	49.0	7	12.5	45	61.5
Severe RI	[redacted]					
Missing						
Trial product pen-injector						
N	800	1335.3	395	627.0	1195	1962.3
DV3396	520	1120.6	252	520.1	772	1640.7
PDS290	280	214.7	143	106.9	423	321.6
Region						
N	800	1335.3	395	627.0	1195	1962.3
Europe	217	362.0	86	131.3	303	493.3
North America	259	439.4	145	213.3	404	652.7
South America	73	104.7	34	56.2	107	160.9
Asia	200	333.8	103	174.7	303	508.5
Other	51	95.4	27	51.5	78	146.8
Lean NASH at baseline						
N	800	1335.3	395	627.0	1195	1962.3
With lean NASH	23	30.1	12	17.7	35	47.8
Without lean NASH	769	1288.3	380	603.1	1149	1891.5
Missing	8	16.8	3	6.2	11	23.0

AIAN: American Indian or Alaskan Native, ALT: Alanine Aminotransferase, AST: Aspartate Aminotransferase, DV3396: Single-dose pen-injector, N: Number of subjects, NT2D: Subjects without a type 2 diabetes diagnosis at baseline, PDS290: Multi-dose pen-injector, PYE: Person-years of exposure, RI: Renal impairment, T2D: Type 2 diabetes, ULN: Upper limit of normal range. ALP: Alkaline Phosphatase. Lean NASH: Body mass index <25 for non-Asian subjects and body mass index <23 for Asian subjects. Renal impairment is classified as Normal (eGFR >=90 mL/min/1.73 m2), Mild (eGFR >=60 to <90 mL/min/1.73 m2), Moderate (eGFR >= 30 to <60 mL/min/1.73 m2), Severe (eGFR >= 15 to <30 mL/min/1.73 m2).

ウゴービ皮下注
非アルコール性脂肪肝炎（NASH）

2.7.4.7 付録
2.特別な患者集団及び状況下における安全性

ノボ ノルディスク ファーマ株式会社

Table of contents

Page

7.2.1 Adverse events by sex - overview - on-treatment - safety analysis set (interim) - trial 4553 7
7.2.2 Adverse events by sex, system organ class and preferred term - summary - on-treatment - safety analysis set (interim) - trial 4553 11
7.2.3 Adverse events by sex and system organ class – dot plot – on-treatment – safety analysis set (interim) - trial 4553 154
7.2.4 Adverse events by sex and preferred term – most frequent (>=5%) – dot plot – on-treatment – safety analysis set (interim) - trial 4553 155
7.2.5 Adverse events overview by sex - bar plot - on-treatment - safety analysis set (interim) - trial 4553 156
7.2.6 Adverse events by age at baseline - overview - on-treatment - safety analysis set (interim) - trial 4553 157
7.2.7 Adverse events by age at baseline, system organ class and preferred term - summary - on-treatment - safety analysis set (interim) - trial 4553 161
7.2.8 Adverse events by age at baseline and system organ class – dot plot – on-treatment – safety analysis set (interim) - trial 4553 310
7.2.9 Adverse events by age at baseline and preferred term – most frequent (>=5%) – dot plot – on-treatment – safety analysis set (interim) - trial 4553 311
7.2.10 Adverse events overview by age at baseline - bar plot - on-treatment - safety analysis set (interim) - trial 4553 312
7.2.11 Adverse events by race - overview - on-treatment - safety analysis set (interim) - trial 4553 313
7.2.12 Adverse events by race, system organ class and preferred term - summary - on-treatment - safety analysis set (interim) - trial 4553 321
7.2.13 Adverse events by race and system organ class - dot plot - on-treatment - safety analysis set (interim) - trial 4553 470
7.2.14 Adverse events by race and preferred term – most frequent (>=5%) - dot plot - on-treatment - safety analysis set (interim) - trial 4553 471
7.2.15 Adverse events overview by race - bar plot - on-treatment - safety analysis set (interim) - trial 4553 472
7.2.16 Adverse events by ethnicity - overview - on-treatment - safety analysis set (interim) - trial 4553 473
7.2.17 Adverse events by ethnicity, system organ class and preferred term - summary - on-treatment - safety analysis set (interim) - trial 4553 481
7.2.18 Adverse events by ethnicity and system organ class - dot plot - on-treatment - safety analysis set (interim) - trial 4553 746
7.2.19 Adverse events by ethnicity and preferred term – most frequent (>=5%) - dot plot - on-treatment - safety analysis set (interim) - trial 4553 747
7.2.20 Adverse events overview by ethnicity - bar plot - on-treatment - safety analysis set (interim) - trial 4553 748
7.2.21 Adverse events by diabetes status at baseline - overview - on-treatment - safety analysis set (interim) - trial 4553 749
7.2.22 Adverse events by diabetes status at baseline, system organ class and preferred term - summary - on-treatment - safety analysis set (interim) - trial 4553 753
7.2.23 Adverse events by diabetes status at baseline and system organ class - dot plot - on-treatment - safety analysis set (interim) - trial 4553 899
7.2.24 Adverse events by diabetes status at baseline and preferred term – most frequent (>=5%) - dot plot - on-treatment - safety analysis set (interim) - trial 4553 900

7.2.25 Adverse events overview by diabetes status at baseline - bar plot - on-treatment - safety analysis set (interim) - trial 4553 901
7.2.26 Adverse events by glycaemic status at baseline - overview - on-treatment - safety analysis set (interim) (only subjects without type 2 diabetes at baseline) - trial 4553 902
7.2.27 Adverse events by glycaemic status at baseline, system organ class and preferred term - summary - on-treatment - safety analysis set (interim) (only subjects without type 2 diabetes at baseline) - trial 4553 909
7.2.28 Adverse events by glycaemic status at baseline and system organ class - dot plot - on-treatment - safety analysis set (interim) (only subjects without type 2 diabetes at baseline) - trial 4553 1053
7.2.29 Adverse events by glycaemic status at baseline and preferred term – most frequent (>=5%) - dot plot - on-treatment - safety analysis set (interim) (only subjects without type 2 diabetes at baseline) - trial 4553 1054
7.2.30 Adverse events overview by glycaemic status at baseline - bar plot - on-treatment - safety analysis set (interim) (only subjects without type 2 diabetes at baseline) - trial 4553 1055
7.2.31 Adverse events by fibrosis stage at baseline - overview - on-treatment - safety analysis set (interim) - trial 4553 1056
7.2.32 Adverse events by fibrosis stage at baseline, system organ class and preferred term - summary - on-treatment - safety analysis set (interim) - trial 4553 1060
7.2.33 Adverse events by fibrosis stage at baseline and system organ class - dot plot - on-treatment - safety analysis set (interim) - trial 4553 1205
7.2.34 Adverse events by fibrosis stage at baseline and preferred term – most frequent (>=5%) - dot plot - on-treatment - safety analysis set (interim) - trial 4553 1206
7.2.35 Adverse events overview by fibrosis stage at baseline - bar plot - on-treatment - safety analysis set (interim) - trial 4553 1207
7.2.36 Adverse events by BMI at baseline - overview - on-treatment - safety analysis set (interim) - trial 4553 1208
7.2.37 Adverse events by BMI at baseline, system organ class and preferred term - summary - on-treatment - safety analysis set (interim) - trial 4553 1215
7.2.38 Adverse events by BMI at baseline and system organ class - dot plot - on-treatment - safety analysis set (interim) - trial 4553 1374
7.2.39 Adverse events by BMI at baseline and preferred term – most frequent (>=5%) - dot plot - on-treatment - safety - trial 4553 analysis set 1375
7.2.40 Adverse events overview by BMI at baseline - bar plot - on-treatment - safety analysis set (interim) - trial 4553 1376
7.2.41 Adverse events by BMI at baseline (<27 or >=27) - overview - on-treatment - safety analysis set (interim) - trial 4553 1377
7.2.42 Adverse events by BMI at baseline (<27 or >=27), system organ class and preferred term - summary - on-treatment - safety analysis set (interim) - trial 4553 1381
7.2.43 Adverse events by BMI at baseline (<27 or >=27) and system organ class - dot plot - on-treatment - safety analysis set (interim) - trial 4553 1518
7.2.44 Adverse events by BMI at baseline (<27 or >=27) and preferred term – most frequent (>=5%) - dot plot - on-treatment - safety - trial 4553 analysis set 1519
7.2.45 Adverse events overview by BMI at baseline (<27 or >=27) - bar plot - on-treatment - safety analysis set (interim) - trial 4553 1520
7.2.46 Adverse events by Aspartate Aminotransferase (AST) at baseline - overview - on-treatment - safety analysis set (interim) - trial 4553 1521
7.2.47 Adverse events by Aspartate Aminotransferase (AST) at baseline, system organ class and preferred term - summary - on-treatment - safety analysis set (interim) - trial 4553 1527

7.2.48 Adverse events by Aspartate Aminotransferase (AST) at baseline and system organ class - dot plot - on-treatment - safety analysis set (interim) - trial 4553 1731
7.2.49 Adverse events by Aspartate Aminotransferase (AST) at baseline and preferred term – most frequent (>=5%) - dot plot - on-treatment - safety analysis set (interim) - trial 4553 1732
7.2.50 Adverse events overview by Aspartate Aminotransferase (AST) at baseline - bar plot - on-treatment - safety analysis set (interim) - trial 4553 1733
7.2.51 Adverse events by Alanine Aminotransferase (ALT) at baseline - overview - on-treatment - safety analysis set (interim) - trial 4553 1734
7.2.52 Adverse events by Alanine Aminotransferase (ALT) at baseline, system organ class and preferred term - summary - on-treatment - safety analysis set (interim) - trial 4553 1740
7.2.53 Adverse events by Alanine Aminotransferase (ALT) at baseline and system organ class - dot plot - on-treatment - safety analysis set (interim) - trial 4553 1925
7.2.54 Adverse events by Alanine Aminotransferase (ALT) at baseline and preferred term – most frequent (>=5%) - dot plot - on-treatment - safety analysis set (interim) - trial 4553 1926
7.2.55 Adverse events overview by Alanine Aminotransferase (ALT) at baseline - bar plot - on-treatment - safety analysis set (interim) - trial 4553 1927
7.2.56 Adverse events by Alkaline Phosphatase (ALP) at baseline - overview - on-treatment - safety analysis set (interim) - trial 4553 1928
7.2.57 Adverse events by Alkaline Phosphatase (ALP) at baseline, system organ class and preferred term - summary - on-treatment - safety analysis set (interim) - trial 4553 1932
7.2.58 Adverse events by Alkaline Phosphatase (ALP) at baseline and system organ class - dot plot - on-treatment - safety analysis set (interim) - trial 4553 2069
7.2.59 Adverse events by Alkaline Phosphatase (ALP) at baseline and preferred term – most frequent (>=5%) - dot plot - on-treatment - safety analysis set (interim) - trial 4553 2070
7.2.60 Adverse events overview by Alkaline Phosphatase (ALP) at baseline - bar plot - on-treatment - safety analysis set (interim) - trial 4553 2071
7.2.61 Adverse events by renal function at baseline - overview - on-treatment - safety analysis set (interim) - trial 4553 2072
7.2.62 Adverse events by renal function at baseline, system organ class and preferred term - summary - on-treatment - safety analysis set (interim) - trial 4553 2078
7.2.63 Adverse events by renal function at baseline and system organ class - dot plot - on-treatment - safety analysis set (interim) - trial 4553 2245
7.2.64 Adverse events by renal function at baseline and preferred term – most frequent (>=5%) - dot plot - on-treatment - safety analysis set (interim) - trial 4553 2246
7.2.65 Adverse events overview by renal function at baseline - bar plot - on-treatment - safety analysis set (interim) - trial 4553 2247
7.2.66 Adverse events by trial product pen-injector - overview - on-treatment - safety analysis set (interim) - trial 4553 2248
7.2.67 Adverse events by trial product pen-injector, system organ class and preferred term - summary - on-treatment - safety analysis set (interim) - trial 4553 2252
7.2.68 Adverse events by trial product pen-injector and system organ class - dot plot - on-treatment - safety analysis set (interim) - trial 4553 2396
7.2.69 Adverse events by trial product pen-injector and preferred term – most frequent (>=5%) - dot plot - on-treatment - safety analysis set (interim) - trial 4553 2397
7.2.70 Adverse events overview by trial product pen-injector - bar plot - on-treatment - safety analysis set (interim) - trial 4553 2398
7.2.71 Adverse events by region - overview - on-treatment - safety analysis set (interim) - trial 4553 2399


7.2.72 Adverse events by region, system organ class and preferred term - summary - on-treatment - safety analysis set (interim) - trial 4553 2407
7.2.73 Adverse events by region and system organ class - dot plot - on-treatment - safety analysis set (interim) - trial 4553 2590
7.2.74 Adverse events by region and preferred term – most frequent (>=5%) - dot plot - on-treatment - safety analysis set (interim) - trial 4553 2591
7.2.75 Adverse events overview by region - bar plot - on-treatment - safety analysis set (interim) - trial 4553 2592
7.2.76 Adverse events by lean NASH status at baseline - overview - on-treatment - safety analysis set (interim) - trial 4553 2593
7.2.77 Adverse events by lean NASH, system organ class and preferred term - summary - on-treatment - safety analysis set (interim) - trial 4553 2600
7.2.78 Adverse events by lean NASH status at baseline and system organ class - dot plot - on-treatment - safety analysis set (interim) - trial 4553 2806
7.2.79 Adverse events by lean NASH status at baseline and preferred term – most frequent (>=5%) - dot plot - on-treatment - safety analysis set (interim) - trial 4553 2807
7.2.80 Adverse events overview by lean NASH status at baseline - bar plot - on-treatment - safety analysis set (interim) - trial 4553 2808
7.2.81 Adverse events for subjects with baseline fibrosis stage 2 or 3 by system organ class - summary plot - on-treatment - safety analysis set - trial 4296 2809
7.2.82 Adverse events for subjects with baseline fibrosis stage 2 or 3 by preferred term - most frequent (>=10%) - summary plot - on-treatment - safety analysis set - trial 4296 2810

7.2 Safety in special groups and situations

付録２において以下の図以外の頁を省略する。

7.2.5 Adverse events overview by sex
7.2.10 Adverse events overview by age at baseline
7.2.15 Adverse events overview by race
7.2.20 Adverse events overview by ethnicity
7.2.25 Adverse events overview by diabetes status at baseline
7.2.30 Adverse events overview by glycaemic status at baseline (only subjects without type 2 diabetes at baseline)
7.2.35 Adverse events overview by fibrosis stage at baseline
7.2.40 Adverse events overview by BMI at baseline
7.2.45 Adverse events overview by BMI at baseline (<27 or >=27)
7.2.50 Adverse events overview by Aspartate Aminotransferase (AST) at baseline
7.2.55 Adverse events overview by Alanine Aminotransferase (ALT) at baseline
7.2.60 Adverse events overview by Alkaline Phosphatase (ALP) at baseline
7.2.65 Adverse events overview by renal function at baseline
7.2.70 Adverse events overview by trial product pen-injector
7.2.75 Adverse events overview by region
7.2.80 Adverse events overview by lean NASH status at baseline
7.2.81 Adverse events for subjects with baseline fibrosis stage 2 or 3 by system organ class - summary plot - on-treatment - safety analysis set - trial 4296
7.2.82 Adverse events for subjects with baseline fibrosis stage 2 or 3 by preferred term - most frequent (>=10%) - summary plot - on-treatment - safety analysis set - trial 4296


7.2.5 Adverse events overview by sex - bar plot - on-treatment - safety analysis set (interim) - trial 4553



%: Percentage of subjects with at least one event, AE: Adverse event, N: Number of subjects. Adverse events with onset date during on-treatment period. Discontinuation: Adverse events leading to premature trial product discontinuation.

nn9931/nn9931-submission-level1/safety_l1_20250130_er
30JAN2025:09:37:03 - faebaroverviewgrp.sas/faebaroverviewsexot.png


7.2.10 Adverse events overview by age at baseline - bar plot - on-treatment - safety analysis set (interim) - trial 4553



%: Percentage of subjects with at least one event, AE: Adverse event, N: Number of subjects. Adverse events with onset date during on-treatment period. Discontinuation: Adverse events leading to premature trial product discontinuation.

nn9931/nn9931-submission-level1/safety_l1_20250130_er
30JAN2025:09:37:15 - faebaroverviewgrp.sas/faebaroverviewageot.png


7.2.15 Adverse events overview by race - bar plot - on-treatment - safety analysis set (interim) - trial 4553



%: Percentage of subjects with at least one event, AE: Adverse event, AIAN: American Indian or Alaskan Native, N: Number of subjects. Adverse events with onset date during on-treatment period. Discontinuation: Adverse events leading to premature trial product discontinuation.

nn9931/nn9931-submission-level1/safety_l1_20250130_er
30JAN2025:09:37:22 - faebaroverviewgrp.sas/faebaroverviewraceot.png


7.2.20 Adverse events overview by ethnicity - bar plot - on-treatment - safety analysis set (interim) - trial 4553



%: Percentage of subjects with at least one event, AE: Adverse event, N: Number of subjects. Adverse events with onset date during on-treatment period. Discontinuation: Adverse events leading to premature trial product discontinuation.

nn9931/nn9931-submission-level1/safety_l1_20250130_er
30JAN2025:09:37:30 - faebaroverviewgrp.sas/faebaroverviewethnicot.png


7.2.25 Adverse events overview by diabetes status at baseline - bar plot - on-treatment - safety analysis set (interim) - trial 4553



%: Percentage of subjects with at least one event, AE: Adverse event, N: Number of subjects, NT2D: Subjects without a type 2 diabetes diagnosis at baseline, T2D: Type 2 diabetes. Adverse events with onset date during on-treatment period. Discontinuation: Adverse events leading to premature trial product discontinuation.

nn9931/nn9931-submission-level1/safety_l1_20250130_er
30JAN2025:09:37:36 - faebaroverviewgrp.sas/faebaroverviewdiabot.png


7.2.30 Adverse events overview by glycaemic status at baseline - bar plot - on-treatment - safety analysis set (interim) (only subjects without type 2 diabetes at baseline) - trial 4553



%: Percentage of subjects with at least one event, AE: Adverse event, N: Number of subjects. Adverse events with onset date during on-treatment period. Discontinuation: Adverse events leading to premature trial product discontinuation.

nn9931/nn9931-submission-level1/safety_l1_20250130_er
30JAN2025:09:37:42 - faebaroverviewgrp.sas/faebaroverviewhba1cot.png


7.2.35 Adverse events overview by fibrosis stage at baseline - bar plot - on-treatment - safety analysis set (interim) - trial 4553



%: Percentage of subjects with at least one event, AE: Adverse event, F2: Fibrosis stage 2 at baseline, F3: Fibrosis stage 3 at baseline, N: Number of subjects. Adverse events with onset date during on-treatment period. Discontinuation: Adverse events leading to premature trial product discontinuation.

nn9931/nn9931-submission-level1/safety_l1_20250130_er
30JAN2025:09:37:51 - faebaroverviewgrp.sas/faebaroverviewfibot.png


7.2.40 Adverse events overview by BMI at baseline - bar plot - on-treatment - safety analysis set (interim) - trial 4553



%: Percentage of subjects with at least one event, AE: Adverse event, BMI: Body mass index (kg/m2), N: Number of subjects. Adverse events with onset date during on-treatment period. Discontinuation: Adverse events leading to premature trial product discontinuation.

nn9931/nn9931-submission-level1/safety_l1_20250130_er
30JAN2025:09:38:00 - faebaroverviewgrp.sas/faebaroverviewbmiot.png


7.2.45 Adverse events overview by BMI at baseline (<27 or >=27) - bar plot - on-treatment - safety analysis set (interim) - trial 4553



%: Percentage of subjects with at least one event, AE: Adverse event, BMI: Body mass index (kg/m2), N: Number of subjects. Adverse events with onset date during on-treatment period. Discontinuation: Adverse events leading to premature trial product discontinuation.

nn9931/nn9931-submission-level1/safety_l1_20250130_er
30JAN2025:09:39:06 - faebaroverviewgrp.sas/faebaroverviewbmi27ot.png


7.2.50 Adverse events overview by Aspartate Aminotransferase (AST) at baseline - bar plot - on-treatment - safety analysis set (interim) - trial 4553



%: Percentage of subjects with at least one event, AE: Adverse event, N: Number of subjects, ULN: Upper limit of normal range. Adverse events with onset date during on-treatment period. Discontinuation: Adverse events leading to premature trial product discontinuation.

nn9931/nn9931-submission-level1/safety_l1_20250130_er
30JAN2025:09:38:08 - faebaroverviewgrp.sas/faebaroverviewastot.png


7.2.55 Adverse events overview by Alanine Aminotransferase (ALT) at baseline - bar plot - on-treatment - safety analysis set (interim) - trial 4553



%: Percentage of subjects with at least one event, AE: Adverse event, N: Number of subjects, ULN: Upper limit of normal range. Adverse events with onset date during on-treatment period. Discontinuation: Adverse events leading to premature trial product discontinuation.

nn9931/nn9931-submission-level1/safety_l1_20250130_er
30JAN2025:09:38:22 - faebaroverviewgrp.sas/faebaroverviewaltot.png


7.2.60 Adverse events overview by Alkaline Phosphatase (ALP) at baseline - bar plot - on-treatment - safety analysis set (interim) - trial 4553



%: Percentage of subjects with at least one event, AE: Adverse event, N: Number of subjects, ULN: Upper limit of normal range. Adverse events with onset date during on-treatment period. Discontinuation: Adverse events leading to premature trial product discontinuation.

nn9931/nn9931-submission-level1/safety_l1_20250130_er
30JAN2025:09:38:32 - faebaroverviewgrp.sas/faebaroverviewalpot.png


7.2.65 Adverse events overview by renal function at baseline - bar plot - on-treatment - safety analysis set (interim) - trial 4553



%: Percentage of subjects with at least one event, AE: Adverse event, N: Number of subjects, RI: Renal impairment. Adverse events with onset date during on-treatment period. Discontinuation: Adverse events leading to premature trial product discontinuation. Renal impairment is classified as Normal (eGFR >=90 mL/min/1.73 m2), Mild (eGFR >=60 to <90 mL/min/1.73 m2), Moderate (eGFR >= 30 to <60 mL/min/1.73 m2), Severe (eGFR >= 15 to <30 mL/min/1.73 m2). One subject in the placebo arm with Severe RI has been omitted from this output, as the subject had no adverse events before discontinuing the study on trial day 1.

nn9931/nn9931-submission-level1/safety_l1_20250130_er
30JAN2025:09:38:39 - faebaroverviewgrp.sas/faebaroverviewegfrot.png


7.2.70 Adverse events overview by trial product pen-injector - bar plot - on-treatment - safety analysis set (interim) - trial 4553



%: Percentage of subjects with at least one event, AE: Adverse event, DV3396: Single-dose pen-injector, N: Number of subjects, PDS290: Multi-dose pen-injector. Adverse events with onset date during on-treatment period. Discontinuation: Adverse events leading to premature trial product discontinuation.

nn9931/nn9931-submission-level1/safety_l1_20250130_er
30JAN2025:09:38:50 - faebaroverviewgrp.sas/faebaroverviewdeviceot.png


7.2.75 Adverse events overview by region - bar plot - on-treatment - safety analysis set (interim) - trial 4553



%: Percentage of subjects with at least one event, AE: Adverse event, N: Number of subjects. Adverse events with onset date during on-treatment period. Discontinuation: Adverse events leading to premature trial product discontinuation.

nn9931/nn9931-submission-level1/safety_l1_20250130_er
30JAN2025:09:38:59 - faebaroverviewgrp.sas/faebaroverviewregionot.png

7.2.80 Adverse events overview by lean NASH status at baseline - bar plot - on-treatment - safety analysis set (interim) - trial 4553




%: Percentage of subjects with at least one event, AE: Adverse event, N: Number of subjects. Adverse events with onset date during on-treatment period. Discontinuation: Adverse events leading to premature trial product discontinuation. Lean NASH: Body mass index <25 for non-Asian subjects and body mass index <23 for Asian subjects.

nn9931/nn9931-submission-level1/safety_l1_20250130_er
30JAN2025:09:39:14 - faebaroverviewgrp.sas/faebaroverviewleanot.png

7.2.81 Adverse events for subjects with baseline fibrosis stage 2 or 3 by system organ class - summary plot - on-treatment - safety analysis set - trial 4296


System organ class	Sema 0.1 mg OD N	%	R	Sema 0.2 mg OD N	%	R	Sema 0.4 mg OD N	%	R	Placebo N	%	R
Gastrointestinal disorders	37	64.9	146.2	48	81.4	205.3	39	70.9	171.1	29	50.0	77.1
Infections and infestations	35	61.4	74.3	28	47.5	86.7	17	30.9	39.0	27	46.6	54.2
General disorders and administration site conditions	19	33.3	35.3	20	33.9	39.5	15	27.3	25.2	20	34.5	42.2
Nervous system disorders	17	29.8	37.8	17	28.8	42.1	16	29.1	25.2	16	27.6	37.3
Musculoskeletal and connective tissue disorders	15	26.3	28.0	18	30.5	35.7	16	29.1	28.9	16	27.6	48.2
Metabolism and nutrition disorders	14	24.6	20.7	18	30.5	26.8	16	29.1	31.5	15	25.9	20.5
Investigations	11	19.3	29.2	19	32.2	35.7	9	16.4	25.2	14	24.1	25.3
Injury, poisoning and procedural complications	16	28.1	24.4	7	11.9	12.7	8	14.5	12.6	7	12.1	14.5
Skin and subcutaneous tissue disorders	9	15.8	13.4	12	20.3	19.1	8	14.5	11.3	6	10.3	10.8
Respiratory, thoracic and mediastinal disorders	10	17.5	19.5	6	10.2	8.9	4	7.3	5.0	9	15.5	14.5
Renal and urinary disorders	6	10.5	7.3	5	8.5	8.9	6	10.9	7.5	8	13.8	10.8
Vascular disorders	8	14.0	11.0	6	10.2	8.9	3	5.5	5.0	5	8.6	6.0
Psychiatric disorders	5	8.8	9.7	4	6.8	5.1	3	5.5	3.8	5	8.6	10.8
Eye disorders	1	1.8	1.2	5	8.5	7.6	6	10.9	7.5	3	5.2	6.0
Neoplasms benign, malignant and unspecified	5	8.8	7.3	4	6.8	5.1	3	5.5	3.8	2	3.4	2.4
Blood and lymphatic system disorders	4	7.0	4.9	3	5.1	6.4	0			4	6.9	6.0
Ear and labyrinth disorders	4	7.0	4.9	2	3.4	3.8	1	1.8	1.3	4	6.9	4.8
Reproductive system and breast disorders	3	5.3	3.7	3	5.1	3.8	0			5	8.6	7.2
Cardiac disorders	1	1.8	1.2	2	3.4	3.8	4	7.3	5.0	1	1.7	4.8
Hepatobiliary disorders	1	1.8	1.2	5	8.5	11.5	2	3.6	2.5	0		
Immune system disorders	3	5.3	3.7	3	5.1	3.8	1	1.8	1.3	1	1.7	1.2
Endocrine disorders	0			2	3.4	2.5	1	1.8	1.3	2	3.4	2.4
Surgical and medical procedures	0			1	1.7	1.3	2	3.6	2.5	0		
Congenital, familial and genetic disorders	0			0			1	1.8	1.3	0		



%: Percentage of subjects with at least one event, N: Number of subjects with at least one event, OD: Once daily, R: Event rate (number of events per 100 years of exposure). MedDRA version 22.1.

nn9931/nn9931-submission-level1/safety_l1_20250130_er
30JAN2025:09:37:01 - faesummary4296.sas/faesummarysocfib23.png

7.2.82 Adverse events for subjects with baseline fibrosis stage 2 or 3 by preferred term - most frequent (>=10%) - summary plot - on-treatment - safety analysis set - trial 4296



Preferred term	Sema 0.1 mg OD N	%	R	Sema 0.2 mg OD N	%	R	Sema 0.4 mg OD N	%	R	Placebo N	%	R
Nausea	15	26.3	25.6	22	37.3	33.1	24	43.6	41.5	8	13.8	10.8
Diarrhoea	21	36.8	35.3	17	28.8	29.3	13	23.6	21.4	8	13.8	13.3
Constipation	10	17.5	13.4	13	22.0	22.9	11	20.0	16.4	10	17.2	13.3
Decreased appetite	10	17.5	14.6	11	18.6	14.0	11	20.0	16.4	4	6.9	4.8
Nasopharyngitis	7	12.3	12.2	12	20.3	21.7	5	9.1	7.5	10	17.2	15.7
Vomiting	8	14.0	17.1	15	25.4	28.0	7	12.7	21.4	2	3.4	3.6
Headache	5	8.8	8.5	10	16.9	16.6	8	14.5	10.1	6	10.3	9.6
Fatigue	6	10.5	7.3	6	10.2	7.6	4	7.3	5.0	7	12.1	8.4
Abdominal pain	8	14.0	11.0	7	11.9	10.2	4	7.3	6.3	2	3.4	3.6
Back pain	4	7.0	6.1	4	6.8	5.1	6	10.9	7.5	7	12.1	8.4
Dyspepsia	3	5.3	3.7	6	10.2	8.9	2	3.6	3.8	4	6.9	7.2
Abdominal distension	1	1.8	1.2	7	11.9	10.2	2	3.6	5.0	3	5.2	4.8
Arthralgia	0			3	5.1	3.8	4	7.3	5.0	6	10.3	7.2

%: Percentage of subjects with at least one event, N: Number of subjects with at least one event, OD: Once daily, R: Event rate (number of events per 100 years of exposure). MedDRA version 22.1.

nn9931/nn9931-submission-level1/safety_l1_20250130_er
30JAN2025:09:37:09 - faesummary4296.sas/faesummarypt10fib23.png

ウゴービ皮下注
非アルコール性脂肪肝炎（NASH）

2.7.4.7 付録
3.グループ化した有害事象及び単一の基本語

ノボ ノルディスク ファーマ株式会社

Table of contents

Page

7.3.1 Gastrointestinal disorders - abdominal pain - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553 4
7.3.2 Gastrointestinal disorders - gastritis - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553 6
7.3.3 Fatigue - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553 8
7.3.4 Increased amylase - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553 10
7.3.5 Increased lipase - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553 12
7.3.6 Increased heart rate - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553 14
7.3.7 Dysgeusia - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553 16
7.3.8 Cholecystitis - grouped preferred terms - overview - on-treatment – safety analysis set (interim) - trial 4553 18
7.3.9 Dysaesthesia - grouped preferred terms - overview - on-treatment – safety analysis set (interim) - trial 4553 20
7.3.10 Intestinal obstruction - grouped preferred terms - overview - on-treatment – safety analysis set (interim) - trial 4553 22
7.3.11 Hair loss - single lowest level term - overview - on-treatment – safety analysis set (interim) - trial 4553 24
7.3.12 Headache - single preferred term - overview - on-treatment – safety analysis set (interim) - trial 4553 26

7.3 Grouped adverse event terms

7.3.1 Gastrointestinal disorders - abdominal pain - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553

	Sema 2.4 mg						Placebo						Total					
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Number of subjects	800						395						1195					
Observation time (years)	1335.26						627.03						1962.28					
Events	148	(18.5)	1105.3	13.4	212	15.8	65	(16.5)	548.1	11.9	91	14.5	213	(17.8)	1653.4	12.9	303	15.4
Serious																		
Yes																		
No	147	(18.4)	1106.8	13.3	211	15.8	65	(16.5)	548.1	11.9	91	14.5	212	(17.7)	1654.9	12.8	302	15.3
Severity																		
Severe																		
Moderate	42	(5.3)	1273.8	3.3	49	3.6	17	(4.3)	612.7	2.8	19	3.0	59	(4.9)	1886.5	3.1	68	3.4
Mild	114	(14.3)	1161.1	9.8	160	11.9	54	(13.7)	556.3	9.7	72	11.4	168	(14.1)	1717.4	9.8	232	11.8
Relationship to trial product																		
Probable	50	(6.3)	1254.0	4.0	67	5.0	11	(2.8)	615.4	1.8	16	2.5	61	(5.1)	1869.3	3.3	83	4.2
Possible	56	(7.0)	1256.4	4.5	74	5.5	27	(6.8)	590.7	4.6	33	5.2	83	(6.9)	1847.1	4.5	107	5.4
Unlikely	56	(7.0)	1249.1	4.5	71	5.3	37	(9.4)	588.4	6.3	42	6.7	93	(7.8)	1837.5	5.1	113	5.7
Action taken to trial product																		
Drug interrupted	7	(0.9)	1325.6	0.5	7	0.5	5	(1.3)	624.7	0.8	5	0.8	12	(1.0)	1950.3	0.6	12	0.6
Drug withdrawn	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose reduced	11	(1.4)	1318.5	0.8	12	0.9	1	(0.3)	626.2	0.2	1	0.1	12	(1.0)	1944.7	0.6	13	0.6
Dose increased	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose not changed	141	(17.6)	1117.8	12.6	193	14.4	62	(15.7)	549.9	11.3	85	13.5	203	(17.0)	1667.7	12.2	278	14.1
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not applicable	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with the following preferred terms - Abdominal pain, Abdominal pain upper, Abdominal pain lower, Gastrointestinal pain, Abdominal tenderness, Abdominal discomfort, Epigastric discomfort. MedDRA version 27.0.

Gastrointestinal disorders - abdominal pain - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553

	Sema 2.4 mg						Placebo						Total					
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Outcome																		
Fatal	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not recovered	48	(6.0)	1273.6	3.8	48	3.5	17	(4.3)	612.3	2.8	17	2.7	65	(5.4)	1885.9	3.4	65	3.3
Recovered with sequelae	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Recovering	8	(1.0)	1324.2	0.6	10	0.7	3	(0.8)	625.9	0.5	3	0.4	11	(0.9)	1950.1	0.6	13	0.6
Recovered	107	(13.4)	1159.7	9.2	154	11.5	52	(13.2)	558.4	9.3	71	11.3	159	(13.3)	1718.1	9.3	225	11.4
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with the following preferred terms - Abdominal pain, Abdominal pain upper, Abdominal pain lower, Gastrointestinal pain, Abdominal tenderness, Abdominal discomfort, Epigastric discomfort. MedDRA version 27.0.

7.3.2 Gastrointestinal disorders - gastritis - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553

	Sema 2.4 mg						Placebo						Total					
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Number of subjects	800						395						1195					
Observation time (years)	1335.26						627.03						1962.28					
Events	20	(2.5)	1304.8	1.5	21	1.5	10	(2.5)	611.1	1.6	10	1.5	30	(2.5)	1916.0	1.6	31	1.5
Serious																		
Yes	[redacted]																	
No	18	(2.3)	1307.7	1.4	19	1.4	10	(2.5)	611.1	1.6	10	1.5	28	(2.3)	1918.9	1.5	29	1.4
Severity																		
Severe	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Moderate	4	(0.5)	1328.3	0.3	4	0.3	1	(0.3)	625.9	0.2	1	0.1	5	(0.4)	1954.2	0.3	5	0.2
Mild	16	(2.0)	1311.8	1.2	17	1.2	9	(2.3)	612.2	1.5	9	1.4	25	(2.1)	1924.0	1.3	26	1.3
Relationship to trial product																		
Probable	[redacted]																	
Possible																		
Unlikely	10	(1.3)	1320.6	0.8	10	0.7	10	(2.5)	611.1	1.6	10	1.5	20	(1.7)	1931.7	1.0	20	1.0
Action taken to trial product																		
Drug interrupted	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Drug withdrawn	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose reduced	[redacted]																	
Dose increased	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose not changed	19	(2.4)	1306.7	1.5	20	1.5	10	(2.5)	611.1	1.6	10	1.5	29	(2.4)	1917.8	1.5	30	1.5
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not applicable	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with the following preferred terms: Gastritis, Chronic gastritis, Reflux gastritis, Gastritis erosive. MedDRA version 27.0.

Gastrointestinal disorders - gastritis - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553

	Sema 2.4 mg						Placebo						Total					
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Outcome																		
Fatal	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not recovered	12	(1.5)	1317.1	0.9	13	0.9	8	(2.0)	614.0	1.3	8	1.2	20	(1.7)	1931.1	1.0	21	1.0
Recovered with sequelae	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Recovering	[redacted]																	
Recovered	5	(0.6)	1327.8	0.4	5	0.3	2	(0.5)	624.1	0.3	2	0.3	7	(0.6)	1951.9	0.4	7	0.3
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with the following preferred terms: Gastritis, Chronic gastritis, Reflux gastritis, Gastritis erosive. MedDRA version 27.0.

7.3.3 Fatigue - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553

	Sema 2.4 mg						Placebo						Total					
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Number of subjects	800						395						1195					
Observation time (years)	1335.26						627.03						1962.28					
Events	91	(11.4)	1205.7	7.5	106	7.9	29	(7.3)	595.3	4.9	32	5.1	120	(10.0)	1801.0	6.7	138	7.0
Serious																		
Yes	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
No	91	(11.4)	1205.7	7.5	106	7.9	29	(7.3)	595.3	4.9	32	5.1	120	(10.0)	1801.0	6.7	138	7.0
Severity																		
Severe	[redacted]																	
Moderate	21	(2.6)	1305.8	1.6	23	1.7	7	(1.8)	619.2	1.1	7	1.1	28	(2.3)	1924.9	1.5	30	1.5
Mild	74	(9.3)	1229.6	6.0	83	6.2	21	(5.3)	603.9	3.5	24	3.8	95	(7.9)	1833.5	5.2	107	5.4
Relationship to trial product																		
Probable	32	(4.0)	1285.7	2.5	41	3.0	4	(1.0)	622.5	0.6	5	0.8	36	(3.0)	1908.2	1.9	46	2.3
Possible	36	(4.5)	1282.8	2.8	38	2.8	13	(3.3)	612.1	2.1	14	2.2	49	(4.1)	1894.9	2.6	52	2.6
Unlikely	27	(3.4)	1303.4	2.1	27	2.0	12	(3.0)	614.7	2.0	13	2.0	39	(3.3)	1918.2	2.0	40	2.0
Action taken to trial product																		
Drug interrupted	[redacted]																	
Drug withdrawn																		
Dose reduced	6	(0.8)	1325.0	0.5	6	0.4	2	(0.5)	623.9	0.3	2	0.3	8	(0.7)	1948.9	0.4	8	0.4
Dose increased	[redacted]																	
Dose not changed	80	(10.0)	1218.4	6.6	91	6.8	27	(6.8)	598.4	4.5	30	4.7	107	(9.0)	1816.8	5.9	121	6.1
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not applicable	[redacted]																	

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with the following preferred terms: Fatigue, Asthenia. MedDRA version 27.0.

Fatigue - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553

	Sema 2.4 mg						Placebo						Total					
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Outcome																		
Fatal	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not recovered	40	(5.0)	1287.4	3.1	42	3.1	19	(4.8)	607.6	3.1	19	3.0	59	(4.9)	1895.0	3.1	61	3.1
Recovered with sequelae	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Recovering	[redacted]																	
Recovered	52	(6.5)	1253.4	4.1	60	4.4	11	(2.8)	614.6	1.8	13	2.0	63	(5.3)	1868.1	3.4	73	3.7
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with the following preferred terms: Fatigue, Asthenia. MedDRA version 27.0.

7.3.4 Increased amylase - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553

	Sema 2.4 mg						Placebo						Total					
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Number of subjects	800						395						1195					
Observation time (years)	1335.26						627.03						1962.28					
Events	6	(0.8)	1328.8	0.5	8	0.6	2	(0.5)	623.9	0.3	2	0.3	8	(0.7)	1952.7	0.4	10	0.5
Serious																		
Yes	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
No	6	(0.8)	1328.8	0.5	8	0.6	2	(0.5)	623.9	0.3	2	0.3	8	(0.7)	1952.7	0.4	10	0.5
Severity																		
Severe	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Moderate	[redacted]																	
Mild	6	(0.8)	1330.7	0.5	6	0.4	2	(0.5)	623.9	0.3	2	0.3	8	(0.7)	1954.6	0.4	8	0.4
Relationship to trial product																		
Probable	[redacted]																	
Possible	2	(0.3)	1333.9	0.1	2	0.1	2	(0.5)	623.9	0.3	2	0.3	4	(0.3)	1957.8	0.2	4	0.2
Unlikely	[redacted]																	
Action taken to trial product																		
Drug interrupted	[redacted]																	
Drug withdrawn	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose reduced	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose increased	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose not changed	6	(0.8)	1328.8	0.5	7	0.5	2	(0.5)	623.9	0.3	2	0.3	8	(0.7)	1952.7	0.4	9	0.4
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not applicable	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with the following preferred terms: Amylase increased, Amylase abnormal, Hyperamylasaemia, Amylase. MedDRA version 27.0.

Increased amylase - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553

	Sema 2.4 mg						Placebo						Total					
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Outcome																		
Fatal	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not recovered	2	(0.3)	1332.5	0.2	2	0.1	1	(0.3)	626.0	0.2	1	0.1	3	(0.3)	1958.5	0.2	3	0.1
Recovered with sequelae	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Recovering	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Recovered	4	(0.5)	1331.6	0.3	6	0.4	1	(0.3)	624.9	0.2	1	0.1	5	(0.4)	1956.4	0.3	7	0.3
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with the following preferred terms: Amylase increased, Amylase abnormal, Hyperamylasaemia, Amylase. MedDRA version 27.0.

7.3.5 Increased lipase - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553

	Sema 2.4 mg					Placebo					Total				
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Number of subjects	800						395						1195					
Observation time (years)	1335.26						627.03						1962.28					
Events	20	(2.5)	1314.7	1.5	24	1.8	5	(1.3)	618.9	0.8	6	0.9	25	(2.1)	1933.6	1.3	30	1.5
Serious																		
Yes																		
No	19	(2.4)	1315.2	1.4	23	1.7	5	(1.3)	618.9	0.8	6	0.9	24	(2.0)	1934.1	1.2	29	1.4
Severity																		
Severe																		
Moderate	6	(0.8)	1328.8	0.5	7	0.5	1	(0.3)	624.3	0.2	2	0.3	7	(0.6)	1953.1	0.4	9	0.4
Mild	15	(1.9)	1320.2	1.1	16	1.2	4	(1.0)	621.7	0.6	4	0.6	19	(1.6)	1941.9	1.0	20	1.0
Relationship to trial product																		
Probable	7	(0.9)	1327.1	0.5	9	0.6	2	(0.5)	624.9	0.3	2	0.3	9	(0.8)	1952.1	0.5	11	0.5
Possible	9	(1.1)	1325.6	0.7	10	0.7	2	(0.5)	622.1	0.3	2	0.3	11	(0.9)	1947.7	0.6	12	0.6
Unlikely	4	(0.5)	1332.5	0.3	5	0.3	2	(0.5)	624.7	0.3	2	0.3	6	(0.5)	1957.3	0.3	7	0.3
Action taken to trial product																		
Drug interrupted	3	(0.4)	1330.7	0.2	3	0.2	1	(0.3)	624.3	0.2	1	0.1	4	(0.3)	1955.0	0.2	4	0.2
Drug withdrawn	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose reduced	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose increased	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose not changed	17	(2.1)	1317.9	1.3	20	1.5	5	(1.3)	620.5	0.8	5	0.8	22	(1.8)	1938.4	1.1	25	1.2
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not applicable																		

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with the following preferred terms: Lipase increased, Lipase abnormal, Hyperlipasaemia, Lipase. MedDRA version 27.0.

Increased lipase - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553

	Sema 2.4 mg					Placebo					Total				
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Outcome																		
Fatal	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not recovered	10	(1.3)	1326.1	0.8	10	0.7	1	(0.3)	626.1	0.2	1	0.1	11	(0.9)	1952.2	0.6	11	0.5
Recovered with sequelae	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Recovering	[redacted]																	
Recovered	12	(1.5)	1321.6	0.9	13	0.9	4	(1.0)	619.8	0.6	5	0.8	16	(1.3)	1941.4	0.8	18	0.9
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with the following preferred terms: Lipase increased, Lipase abnormal, Hyperlipasaemia, Lipase. MedDRA version 27.0.

7.3.6 Increased heart rate - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553

	Sema 2.4 mg						Placebo						Total					
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Number of subjects	800						395						1195					
Observation time (years)	1335.26						627.03						1962.28					
Events	6	(0.8)	1327.5	0.5	7	0.5	5	(1.3)	619.2	0.8	5	0.8	11	(0.9)	1946.7	0.6	12	0.6
Serious																		
Yes	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
No	6	(0.8)	1327.5	0.5	7	0.5	5	(1.3)	619.2	0.8	5	0.8	11	(0.9)	1946.7	0.6	12	0.6
Severity																		
Severe	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Moderate	2	(0.3)	1332.7	0.2	2	0.1	3	(0.8)	624.2	0.5	3	0.4	5	(0.4)	1957.0	0.3	5	0.2
Mild	5	(0.6)	1330.0	0.4	5	0.3	2	(0.5)	622.0	0.3	2	0.3	7	(0.6)	1952.0	0.4	7	0.3
Relationship to trial product																		
Probable	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Possible	4	(0.5)	1330.1	0.3	5	0.3	1	(0.3)	627.0	0.2	1	0.1	5	(0.4)	1957.1	0.3	6	0.3
Unlikely	2	(0.3)	1332.6	0.2	2	0.1	4	(1.0)	619.2	0.6	4	0.6	6	(0.5)	1951.8	0.3	6	0.3
Action taken to trial product																		
Drug interrupted	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Drug withdrawn	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose reduced	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose increased	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose not changed	6	(0.8)	1327.5	0.5	7	0.5	5	(1.3)	619.2	0.8	5	0.8	11	(0.9)	1946.7	0.6	12	0.6
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not applicable	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with the following preferred terms: Tachycardia, Heart rate increased, Sinus tachycardia. MedDRA version 27.0.

Increased heart rate - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553

	Sema 2.4 mg						Placebo						Total					
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Outcome																		
Fatal	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not recovered	2	(0.3)	1330.6	0.2	2	0.1	2	(0.5)	624.2	0.3	2	0.3	4	(0.3)	1954.8	0.2	4	0.2
Recovered with sequelae	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Recovering	[redacted]																	
Recovered	4	(0.5)	1332.2	0.3	4	0.3	3	(0.8)	621.9	0.5	3	0.4	7	(0.6)	1954.1	0.4	7	0.3
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with the following preferred terms: Tachycardia, Heart rate increased, Sinus tachycardia. MedDRA version 27.0.

7.3.7 Dysgeusia - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553

	Sema 2.4 mg					Placebo					Total				
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Number of subjects	800						395						1195					
Observation time (years)	1335.26						627.03						1962.28					
Events	7	(0.9)	1324.5	0.5	9	0.6	3	(0.8)	621.3	0.5	3	0.4	10	(0.8)	1945.7	0.5	12	0.6
Serious																		
Yes	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
No	7	(0.9)	1324.5	0.5	9	0.6	3	(0.8)	621.3	0.5	3	0.4	10	(0.8)	1945.7	0.5	12	0.6
Severity																		
Severe	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Moderate	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Mild	7	(0.9)	1324.5	0.5	9	0.6	3	(0.8)	621.3	0.5	3	0.4	10	(0.8)	1945.7	0.5	12	0.6
Relationship to trial product																		
Probable	4	(0.5)	1329.6	0.3	4	0.3	2	(0.5)	622.1	0.3	2	0.3	6	(0.5)	1951.6	0.3	6	0.3
Possible	[redacted]																	
Unlikely	1	(0.1)	1333.1	0.1	1	0.0	1	(0.3)	626.2	0.2	1	0.1	2	(0.2)	1959.3	0.1	2	0.1
Action taken to trial product																		
Drug interrupted	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Drug withdrawn	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose reduced	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose increased	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose not changed	7	(0.9)	1324.5	0.5	9	0.6	3	(0.8)	621.3	0.5	3	0.4	10	(0.8)	1945.7	0.5	12	0.6
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not applicable	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). MedDRA version 27.0. Includes adverse events with the following preferred terms: Dysgeusia, Taste disorders.

Dysgeusia - grouped preferred terms - overview - on-treatment - safety analysis set (interim) - trial 4553

	Sema 2.4 mg						Placebo						Total					
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Outcome																		
Fatal	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not recovered	[redacted]																	
Recovered with sequelae	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Recovering	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Recovered	5	(0.6)	1325.0	0.4	6	0.4	3	(0.8)	621.3	0.5	3	0.4	8	(0.7)	1946.2	0.4	9	0.4
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). MedDRA version 27.0. Includes adverse events with the following preferred terms: Dysgeusia, Taste disorders.

7.3.8 Cholecystitis - grouped preferred terms - overview - on-treatment – safety analysis set (interim) - trial 4553

	Sema 2.4 mg						Placebo						Total					
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Number of subjects	800						395						1195					
Observation time (years)	1335.26						627.03						1962.28					
Events																		
Serious																		
Yes																		
No	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Severity																		
Severe																		
Moderate	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Mild	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Relationship to trial product																		
Probable	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Possible																		
Unlikely	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Action taken to trial product																		
Drug interrupted																		
Drug withdrawn	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose reduced	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose increased	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose not changed	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not applicable	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with the following preferred terms: Cholecystitis, Cholecystitis acute. MedDRA version 27.0.

Cholecystitis - grouped preferred terms - overview - on-treatment – safety analysis set (interim) - trial 4553

	Sema 2.4 mg						Placebo						Total					
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Outcome																		
Fatal	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not recovered	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Recovered with sequelae	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Recovering	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Recovered	[redacted]																	
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with the following preferred terms: Cholecystitis, Cholecystitis acute. MedDRA version 27.0.

7.3.9 Dysaesthesia - grouped preferred terms - overview - on-treatment – safety analysis set (interim) - trial 4553

	Sema 2.4 mg					Placebo					Total				
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Number of subjects	800						395						1195					
Observation time (years)	1335.26						627.03						1962.28					
Events	23	(2.9)	1307.8	1.8	28	2.1	6	(1.5)	621.3	1.0	7	1.1	29	(2.4)	1929.1	1.5	35	1.7
Serious																		
Yes	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
No	23	(2.9)	1307.8	1.8	28	2.1	6	(1.5)	621.3	1.0	7	1.1	29	(2.4)	1929.1	1.5	35	1.7
Severity																		
Severe	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Moderate	5	(0.6)	1328.6	0.4	5	0.3	1	(0.3)	625.0	0.2	1	0.1	6	(0.5)	1953.7	0.3	6	0.3
Mild	19	(2.4)	1314.1	1.4	23	1.7	5	(1.3)	623.3	0.8	6	0.9	24	(2.0)	1937.5	1.2	29	1.4
Relationship to trial product																		
Probable	[redacted]																	
Possible	5	(0.6)	1327.3	0.4	6	0.4	2	(0.5)	624.5	0.3	2	0.3	7	(0.6)	1951.8	0.4	8	0.4
Unlikely	14	(1.8)	1320.3	1.1	18	1.3	4	(1.0)	623.9	0.6	5	0.8	18	(1.5)	1944.2	0.9	23	1.1
Action taken to trial product																		
Drug interrupted	[redacted]																	
Drug withdrawn	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose reduced	2	(0.3)	1331.6	0.2	2	0.1	0	(0.0)	0.0	0.0	0	0.0	2	(0.2)	1958.7	0.1	2	0.1
Dose increased	[redacted]																	
Dose not changed	20	(2.5)	1312.6	1.5	24	1.8	6	(1.5)	621.3	1.0	7	1.1	26	(2.2)	1933.9	1.3	31	1.5
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not applicable	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with the following preferred terms: Dysaesthesia, Hyperaesthesia, Paraesthesia, Skin burning sensation, Burning sensation, Pain of skin, Sensitive skin, Skin discomfort, Skin sensitisation, Allodynia, Hyperpathia. MedDRA version 27.0.

Dysaesthesia - grouped preferred terms - overview - on-treatment – safety analysis set (interim) - trial 4553

	Sema 2.4 mg						Placebo						Total					
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Outcome																		
Fatal	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not recovered	12	(1.5)	1322.8	0.9	12	0.9	1	(0.3)	625.0	0.2	1	0.1	13	(1.1)	1947.8	0.7	13	0.6
Recovered with sequelae	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Recovering	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Recovered	12	(1.5)	1320.0	0.9	16	1.2	5	(1.3)	623.3	0.8	6	0.9	17	(1.4)	1943.4	0.9	22	1.1
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with the following preferred terms: Dysaesthesia, Hyperaesthesia, Paraesthesia, Skin burning sensation, Burning sensation, Pain of skin, Sensitive skin, Skin discomfort, Skin sensitisation, Allodynia, Hyperpathia. MedDRA version 27.0.

7.3.10 Intestinal obstruction - grouped preferred terms - overview - on-treatment – safety analysis set (interim) - trial 4553

	Sema 2.4 mg						Placebo						Total					
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Number of subjects	800						395						1195					
Observation time (years)	1335.26						627.03						1962.28					
Events	2	(0.3)	1331.6	0.2	2	0.1	1	(0.3)	626.7	0.2	1	0.1	3	(0.3)	1958.3	0.2	3	0.1
Serious																		
Yes	[redacted]																	
No	1	(0.1)	1333.1	0.1	1	0.0	1	(0.3)	626.7	0.2	1	0.1	2	(0.2)	1959.8	0.1	2	0.1
Severity																		
Severe	1	(0.1)	1333.8	0.1	1	0.0	0	(0.0)	0.0	0.0	0	0.0	1	(0.1)	1960.8	0.1	1	0.0
Moderate	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Mild	1	(0.1)	1333.1	0.1	1	0.0	1	(0.3)	626.7	0.2	1	0.1	2	(0.2)	1959.8	0.1	2	0.1
Relationship to trial product																		
Probable Possible Unlikely	[redacted]																	
Action taken to trial product																		
Drug interrupted	[redacted]																	
Drug withdrawn	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose reduced	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose increased	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose not changed	1	(0.1)	1333.1	0.1	1	0.0	1	(0.3)	626.7	0.2	1	0.1	2	(0.2)	1959.8	0.1	2	0.1
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not applicable	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with the following preferred terms: Intestinal obstruction, Small intestinal obstruction, Ileus. MedDRA version 27.0.

Intestinal obstruction - grouped preferred terms - overview - on-treatment – safety analysis set (interim) - trial 4553

	Sema 2.4 mg						Placebo						Total					
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Outcome																		
Fatal	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not recovered	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Recovered with sequelae	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Recovering	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Recovered	2	(0.3)	1331.6	0.2	2	0.1	1	(0.3)	626.7	0.2	1	0.1	3	(0.3)	1958.3	0.2	3	0.1
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with the following preferred terms: Intestinal obstruction, Small intestinal obstruction, Ileus. MedDRA version 27.0.

7.3.11 Hair loss - single lowest level term - overview - on-treatment – safety analysis set (interim) - trial 4553

	Sema 2.4 mg					Placebo					Total				
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Number of subjects	800						395						1195					
Observation time (years)	1335.26						627.03						1962.28					
Events	13	(1.6)	1312.7	1.0	13	0.9	2	(0.5)	624.8	0.3	2	0.3	15	(1.3)	1937.6	0.8	15	0.7
Serious																		
Yes	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
No	13	(1.6)	1312.7	1.0	13	0.9	2	(0.5)	624.8	0.3	2	0.3	15	(1.3)	1937.6	0.8	15	0.7
Severity																		
Severe	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Moderate	[redacted]																	
Mild	9	(1.1)	1319.2	0.7	9	0.6	2	(0.5)	624.8	0.3	2	0.3	11	(0.9)	1944.0	0.6	11	0.5
Relationship to trial product																		
Probable	2	(0.3)	1332.9	0.2	2	0.1	1	(0.3)	625.7	0.2	1	0.1	3	(0.3)	1958.6	0.2	3	0.1
Possible	[redacted]																	
Unlikely	7	(0.9)	1321.9	0.5	7	0.5	1	(0.3)	626.2	0.2	1	0.1	8	(0.7)	1948.2	0.4	8	0.4
Action taken to trial product																		
Drug interrupted	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Drug withdrawn	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose reduced	[redacted]																	
Dose increased	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose not changed	12	(1.5)	1314.7	0.9	12	0.9	2	(0.5)	624.8	0.3	2	0.3	14	(1.2)	1939.5	0.7	14	0.7
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not applicable	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with preferred terms covered by the low level term 'Hair loss'. MedDRA version 27.0.

Hair loss - single lowest level term - overview - on-treatment – safety analysis set (interim) - trial 4553

	Sema 2.4 mg					Placebo					Total				
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Outcome																		
Fatal	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not recovered	7	(0.9)	1326.5	0.5	7	0.5	1	(0.3)	625.7	0.2	1	0.1	8	(0.7)	1952.1	0.4	8	0.4
Recovered with sequelae	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Recovering	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Recovered	6	(0.8)	1321.5	0.5	6	0.4	1	(0.3)	626.2	0.2	1	0.1	7	(0.6)	1947.7	0.4	7	0.3
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with preferred terms covered by the low level term 'Hair loss'. MedDRA version 27.0.

7.3.12 Headache - single preferred term - overview - on-treatment – safety analysis set (interim) - trial 4553

	Sema 2.4 mg						Placebo						Total					
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Number of subjects	800						395						1195					
Observation time (years)	1335.26						627.03						1962.28					
Events	64	(8.0)	1232.4	5.2	95	7.1	25	(6.3)	594.2	4.2	34	5.4	89	(7.4)	1826.6	4.9	129	6.5
Serious																		
Yes																		
No	64	(8.0)	1232.4	5.2	95	7.1	25	(6.3)	594.2	4.2	33	5.2	89	(7.4)	1826.6	4.9	128	6.5
Severity																		
Severe																		
Moderate	10	(1.3)	1324.0	0.8	11	0.8	4	(1.0)	619.5	0.6	5	0.8	14	(1.2)	1943.5	0.7	16	0.8
Mild	57	(7.1)	1240.3	4.6	84	6.2	24	(6.1)	595.8	4.0	27	4.3	81	(6.8)	1836.1	4.4	111	5.6
Relationship to trial product																		
Probable	14	(1.8)	1310.8	1.1	20	1.5	3	(0.8)	623.3	0.5	4	0.6	17	(1.4)	1934.1	0.9	24	1.2
Possible	28	(3.5)	1290.8	2.2	42	3.1	9	(2.3)	616.3	1.5	12	1.9	37	(3.1)	1907.2	1.9	54	2.7
Unlikely	29	(3.6)	1293.9	2.2	32	2.4	16	(4.1)	604.8	2.6	18	2.8	45	(3.8)	1898.7	2.4	50	2.5
Action taken to trial product																		
Drug interrupted	2	(0.3)	1334.6	0.1	2	0.1	1	(0.3)	625.7	0.2	3	0.4	3	(0.3)	1960.3	0.2	5	0.2
Drug withdrawn	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose reduced	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Dose increased																		
Dose not changed	62	(7.8)	1234.1	5.0	91	6.8	25	(6.3)	594.2	4.2	31	4.9	87	(7.3)	1828.3	4.8	122	6.2
Unknown	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not applicable	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with the following preferred terms: Headache. MedDRA version 27.0.

Headache - single preferred term - overview - on-treatment – safety analysis set (interim) - trial 4553

	Sema 2.4 mg					Placebo					Total				
	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R	N	(%)	PYI	I	E	R
Outcome																		
Fatal	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Not recovered	10	(1.3)	1325.0	0.8	11	0.8	6	(1.5)	617.8	1.0	6	0.9	16	(1.3)	1942.8	0.8	17	0.8
Recovered with sequelae	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0	0	(0.0)	0.0	0.0	0	0.0
Recovering																		
Recovered	54	(6.8)	1242.7	4.3	84	6.2	17	(4.3)	604.4	2.8	26	4.1	71	(5.9)	1847.1	3.8	110	5.6
Unknown																		

%: Percentage of subjects with at least one event, E: Number of events, I: Incidence (number of incident events per 100 PYI), N: Number of subjects with at least one event, PYI : Person-years at risk of incident event, where time at risk is the duration until the first event or the end of the period, whichever comes first, R: Event rate (number of events per 100 years of exposure). Includes adverse events with the following preferred terms: Headache. MedDRA version 27.0.

ウゴービ皮下注
非アルコール性脂肪肝炎（NASH）

2.7.4.7 付録
4. 注目すべき安全性領域で使用した MedDRA 検索

ノボ ノルディスク ファーマ株式会社

Table of contents

Page

Table of contents **2**

List of abbreviations and definitions of terms **3**

1 MedDRA searches for safety focus areas in project NN9931 ..... **4**

2 Trial 4553 (interim DBL), MedDRA version 27.0 ..... **5**

2.1 Abuse/misuse 5
2.2 Acute pancreatitis 5
2.3 Acute renal failure 5
2.4 Allergic reactions 5
2.5 Cardiovascular disorders 5
2.6 COVID-19 6
2.7 Fertility disorders 6
2.8 Gallbladder-related disorders 6
2.9 Gastrointestinal disorders 6
2.10 Hepatic events, comprehensive search 6
2.11 Hepatic events, FMQ Hepatic failure 6
2.12 Hepatic events, FMQ Hepatic injury 6
2.13 Hypoglycemia 6
2.14 Injection site reactions 6
2.15 Malignant neoplasms 6
2.16 Medication errors 6
2.17 Medullary thyroid cancer 7
2.18 Neonatal exposure via breast milk 7
2.19 Neoplasms 7
2.20 Overdose 7
2.21 Pancreatic cancer 7
2.22 Psychiatric disorders 7
2.23 Rare events 8
2.24 Retinal disorders 8
2.25 Suspected transmission of infectious agents 8

3 Trial 4296, MedDRA version 22.1 ..... **9**

3.1 Abuse and misuse 9
3.2 Acute pancreatitis 9
3.3 Gallbladder-related disorders 9
3.4 Gastrointestinal disorders 9
3.5 Hepatic events 10
3.6 Immunogenicity and injection site reactions 10
3.7 Medication errors and overdose 10
3.8 Neoplasms, including malignant neoplasms 10
3.9 Rare events 11
3.10 Retinal disorders 12
3.11 Suspected transmission of infectious agent 12

List of abbreviations and definitions of terms

AE	adverse event
HLGT	high level group term
HLT	high level term
MedDRA	Medical Dictionary for Regulatory Activities
NEC	not elsewhere classified
NNMQ	Novo Nordisk MedDRA query
PT	preferred term
SMQ	standardised MedDRA query
SOC	system organ class

1 MedDRA searches for safety focus areas in project NN9931

The MedDRA search strings in this document (ordered alphabetically) were used for the NN9931 interim submission documents. The same search strings were used for the clinical trial reports.

AEs were coded using the applicable MedDRA version during trial conduct and reported according to the MedDRA version available at the time of DBL for each trial, as listed below:

- Trial 4553 (interim DBL): MedDRA version 27.0
- Trial 4296: MedDRA version 22.1
- Trial 4492: MedDRA version 24.0
- Trial 4381: MedDRA version 22.1

2 Trial 4553 (interim DBL), MedDRA version 27.0

2.1 Abuse/misuse

- SMQ Drug abuse and dependence (narrow terms)
- HLT Intentional product misuses
- PT Poisoning deliberate
- PT Intentional dose omission
- PT Performance enhancing product use
- PT Completed suicide
- PT Intentional self-injury
- PT Suicide attempt
- PT Assisted suicide,
- PT Suspected suicide attempt,
- PT Suspected suicide

2.2 Acute pancreatitis

Custom query (NNMQ Pancreatitis):

- SMQ Acute pancreatitis (narrow terms)
- HLT Acute and chronic pancreatitis (primary and secondary terms)

2.3 Acute renal failure

SMQ Acute renal failure (narrow terms)

2.4 Allergic reactions

Custom query (NNMQ Allergic reactions):

- SMQ Anaphylactic reaction (narrow terms)
- SMQ Angioedema (narrow terms)
- SMQ Severe cutaneous adverse reactions (narrow terms)
- SMQ Anaphylactic/anaphylactoid shock conditions (narrow terms)
- SMQ Hypersensitivity (narrow terms)

2.5 Cardiovascular disorders

Custom query (NNMQ Cardiovascular disorders):

- SMQ Central nervous system vascular disorders (broad and narrow terms)
- SMQ Vasculitis (broad and narrow terms)
- SMQ Ischaemic heart disease (broad and narrow terms)
- SMQ Cardiac arrhythmias (broad and narrow terms)
- SMQ Cardiac failure (broad and narrow terms)
- SMQ Cardiomyopathy (broad and narrow terms)
- SMQ Embolic and thrombotic events (broad and narrow terms)
- SMQ Shock (broad and narrow terms)
- SMQ Torsade de pointes/QT prolongation (broad and narrow terms)

2.6 COVID-19

SMQ COVID-19 (narrow terms)

2.7 Fertility disorders

SMQ Fertility disorders (narrow terms only)

2.8 Gallbladder-related disorders

Custom query (NNMQ Gallbladder-related disorders):

- SMQ Functional, inflammatory and gallstone related biliary disorders (narrow terms)
- SMQ Infectious biliary disorders (narrow terms)

2.9 Gastrointestinal disorders

Custom query (NNMQ Gastrointestinal disorders SOC):

- SOC Gastrointestinal disorders (primary terms)

2.10 Hepatic events, comprehensive search

SMQ Drug related hepatic disorders – comprehensive search (broad and narrow)

2.11 Hepatic events, FMQ Hepatic failure

FDA custom query (FMQ Hepatic failure [broad and narrow terms, version 1.0])

2.12 Hepatic events, FMQ Hepatic injury

FDA custom query (FMQ Hepatic injury [broad and narrow terms, version 2.1])

2.13 Hypoglycemia

SMQ Hypoglycemia (narrow terms)

2.14 Injection site reactions

Custom query (NNMQ Injection Site Reactions):

- HLT Administration site reactions NEC (primary and secondary terms)
- HLT Application and instillation site reactions (primary and secondary terms)
- HLT Infusion site reactions (primary and secondary terms)
- HLT Injection site reactions (primary and secondary terms)

2.15 Malignant neoplasms

SMQ Malignant tumours (narrow terms)

2.16 Medication errors

SMQ Medication errors (narrow terms)

2.17 Medullary thyroid cancer

Custom query (NNMQ MTC):

- PT Medullary thyroid cancer

2.18 Neonatal exposure via breast milk

SMQ Neonatal exposures via breast milk (narrow terms only)

2.19 Neoplasms

Custom query (NNMQ Neoplasms):

- SMQ Biliary neoplasms
- SMQ Breast neoplasms, malignant and unspecified
- SMQ Liver neoplasms, benign (incl cysts and polyps)
- SMQ Liver neoplasms, malignant and unspecified
- SMQ Malignancies
- SMQ Malignant lymphomas
- SMQ Oropharyngeal neoplasms
- SMQ Ovarian neoplasms, malignant and unspecified
- SMQ Premalignant disorders
- SMQ Prostate neoplasms, malignant and unspecified
- SMQ Skin neoplasms, malignant and unspecified
- SMQ Uterine and fallopian tube neoplasms, malignant and unspecified
- SOC Neoplasms benign, malignant and unspecified (incl cysts and polyps) (primary and secondary terms)

2.20 Overdose

Custom query (NNMQ Overdose):

- HLT Overdoses NEC
- PT Accidental overdose
- PT Completed suicide
- PT Suicide attempt
- PT Suspected suicide attempt
- PT Suspected suicide

2.21 Pancreatic cancer

Custom query (NNMQ Pancreatic cancer):

- HLT Pancreatic neoplams (contains secondary terms only)

2.22 Psychiatric disorders

Custom query (used to capture events within psychiatric disorders broadly):

- SOC Psychiatric disorders, primary terms only

2.23 Rare events

Custom query (NNMQ Rare events, deselecting events from other areas):

- SMQ Acute pancreatitis (narrow terms)
- SMQ Agranulocytosis (narrow terms)
- SMQ Guillain-Barre syndrome (narrow terms)
- SMQ Haematopoietic cytopenias affecting more than one type of blood cell (broad and narrow terms)
- SMQ Haematopoietic leukopenia (broad and narrow terms)
- SMQ Haematopoietic thrombocytopenia (narrow terms)
- SMQ Interstitial lung disease (narrow terms)
- SMQ Neuroleptic malignant syndrome (narrow terms)
- SMQ Pseudomembranous colitis (narrow terms only)
- SMQ Retroperitoneal fibrosis (narrow terms only)
- SOC Congenital, familial and genetic disorders, (all terms are primary PTs)
- HLT Acute and chronic pancreatitis (primary and secondary routed PTs)
- HLT Angioedemas (primary and secondary routed PTs)
- HLT Glomerulonephritis and nephrotic syndrome (primary and secondary routed PTs)
- HLT Nephritis NEC (primary and secondary routed PTs)
- PT Disseminated intravascular coagulation
- PT Hepatic lymphocytic infiltration
- PT Multiple organ dysfunction syndrome

2.24 Retinal disorders

Custom query (NNMQ Retinal disorders and visual impairment):

- SMQ Retinal disorders (narrow terms)
- HLT Visual impairment and blindness (excl colour blindness) (primary terms)

2.25 Suspected transmission of infectious agents

Custom query (NNMQ Transmission):

- HLT Infectious disorders carrier (only primary terms)
- HLT Infectious transmissions (only primary terms)

3 Trial 4296, MedDRA version 22.1

3.1 Abuse and misuse

Custom query (NNMQ Abuse Misuse):

- SMQ Drug abuse and dependence (all narrow terms)
- HLT Intentional product misuses
- PT Poisoning deliberate
- PT Intentional dose omission
- PT Performance enhancing product use
- PT Completed suicide
- PT Intentional self-injury
- PT Suicide attempt
- PT Assisted suicide
- PT Suspected suicide attempt
- PT Suspected suicide

3.2 Acute pancreatitis

Custom query (NNMQ Pancreatitis):

- SMQ Acute pancreatitis
- HLT Acute and chronic pancreatitis (including primary and secondary terms)

3.3 Gallbladder-related disorders

Custom query (NNMQ Gallbladder-related disorders):

- SMQ Infectious biliary disorders
- SMQ Functional, inflammatory and gallstone related biliary disorders
    - including all sub-SMQs: Biliary tract disorders, Biliary system related investigations, signs and symptoms, Gallbladder related disorders, Gallstone related disorders

3.4 Gastrointestinal disorders

Custom query (NNMQ Gastrointestinal SOC):

- SOC Gastrointestinal disorders (Primary SOC)

3.5 Hepatic events

Custom query (NNMQ Hepatic events):

- SMQ Hepatic failure, fibrosis and cirrhosis and other liver damage-related conditions (narrow scope terms only)
- HLT Peritoneal infections
- PT Hepatic lymphocytic infiltration
- PT Glycocholic acid increased
- PT Portogram
- PT Portal vein reconstruction
- PT Gallbladder rupture
- PT Malignant biliary obstruction
- PT Hepatobiliary procedural complication

3.6 Immunogenicity and injection site reactions

Custom query (NNMQ Allergic reactions):

- SMQ Anaphylactic reaction
- SMQ Angioedema
- SMQ Severe cutaneous adverse reactions
- SMQ Anaphylactic/anaphylactoid shock conditions
- SMQ Hypersensitivity

Custom query (NNMQ Injection site reactions):

- HLT Administration site reactions NEC
- HLT Application and instillation site reactions
- HLT Infusion site reactions
- HLT Injection site reactions

3.7 Medication errors and overdose

SMQ Medication errors (Broad Scope Terms)

Custom query (NNMQ Overdose):

- HLT Overdoses NEC
- PT Accidental overdose
- PT Completed suicide
- PT Suicide attempt
- PT Suspected suicide attempt
- PT Suspected suicide

3.8 Neoplasms, including malignant neoplasms

Custom query (NNMQ Neoplasms):

- SMQ Biliary neoplasms
- SMQ Breast neoplasms, malignant and unspecified
- SMQ Liver neoplasms, benign (incl cysts and polyps)
- SMQ Liver neoplasms, malignant and unspecified

- SMQ Malignancies
- SMQ Malignant lymphomas
- SMQ Oropharyngeal neoplasms
- SMQ Ovarian neoplasms, malignant and unspecified
- SMQ Premalignant disorders
- SMQ Prostate neoplasms, malignant and unspecified
- SMQ Skin neoplasms, malignant and unspecified
- SMQ Uterine and fallopian tube neoplasms, malignant and unspecified
- SOC Neoplasms benign, malignant and unspecified (incl cysts and polyps), primary and secondary terms

SMQ Malignant tumours

3.9 Rare events

Custom query (NNMQ Rare events):

- SMQ Acute pancreatitis (Narrow scope terms only)
- SMQ Acute renal failure (Narrow scope terms only)
- SMQ Agranulocytosis (Narrow scope terms only)
- SMQ Anaphylactic reaction (Narrow scope terms only)
- SMQ Cardiac arrhythmias (Narrow and Broad Scope Terms)
- SMQ Cholestasis and jaundice of hepatic origin (Narrow and Broad Scope Terms)
- SMQ Guillain-Barre syndrome (Narrow scope terms only)
- SMQ Haematopoietic cytopenias affecting more than one type of blood cell (Narrow and Broad Scope Terms)
- SMQ Haematopoietic leukopenia (Narrow and Broad Scope Terms)
- SMQ Haematopoietic thrombocytopenia (Narrow scope terms only)
- SMQ Hepatic failure, fibrosis and cirrhosis and other liver damage-related conditions (Narrow scope terms only)
- SMQ Hepatitis, non-infectious (Narrow and Broad Scope Terms)
- SMQ Interstitial lung disease (Narrow terms only)
- SMQ Neuroleptic malignant syndrome (Narrow scope terms only)
- SMQ Pseudomembranous colitis (Narrow scope terms only)
- SMQ Retroperitoneal fibrosis (Narrow scope terms only)
- SMQ Severe cutaneous adverse reactions (Narrow scope terms only)
- SOC Congenital, familial and genetic disorders (contains only primary terms)
- HLT Acute and chronic pancreatitis (primary and secondary routed PTs)
- HLT Angioedemas (primary and secondary routed PTs)
- HLT Glomerulonephritis and nephrotic syndrome (primary and secondary routed PTs)
- HLT Nephritis NEC (primary and secondary routed PTs)
- PT Disseminated intravascular coagulation
- PT Multiple organ dysfunction syndrome
- PT Hepatic lymphocytic infiltration

3.10 Retinal disorders

Custom query (NNMQ Retinal disorders and visual impairment):

- SMQ Retinal disorders, narrow terms
- HLT Visual impairment and blindness (excl colour blindness), primary terms

3.11 Suspected transmission of infectious agent

Custom query (NNMQ Transmission):

- HLT Infectious disorders carrier, only primary terms
- HLT Infectious transmissions, only primary terms

ウゴービ皮下注
非アルコール性脂肪肝炎（NASH）

2.7.4.7 付録
5.イベント判定のために使用した基本語検索

ノボ ノルディスク ファーマ株式会社

Table of contents

Page

Table of contents **2**

List of abbreviations and definitions of terms **3**

1 Preferred term query for adjudication – trial NN9931-4553 ..... **4**

2 Acute coronary syndrome **4**

3 Cerebrovascular events **4**

4 Heart Failure **4**

5 Liver-induced MELD score ≥15 ..... **4**

6 Hepatic Decompensation **4**

7 Drug induced liver injury **5**

List of abbreviations and definitions of terms

AE	adverse event
HLT	high level term
MedDRA	Medical Dictionary for Regulatory Activities
PT	preferred term
PTQ	preferred term query
SMQ	standardised MedDRA query

1 Preferred term query for adjudication – trial NN9931-4553

The preferred-term query (PTQ) listed below is a pre-defined list of MedDRA PTs (SMQ's, HLT's or individual PTs), used to screen all reported AEs for events in scope for adjudication during conduct of trial NN9931-4553. The MedDRA version used at time of interim DBL was 27.0.

2 Acute coronary syndrome

SMQ Myocardial infarction, narrow terms only.

3 Cerebrovascular events

The following SMQs, narrow terms only:
Conditions associated with central nervous system haemorrhages and cerebrovascular accidents

- Haemorrhagic central nervous system vascular conditions
- Ischaemic central nervous system vascular conditions (excluding PT's perinatal stroke, vascular stent occlusion, vascular stent stenosis)

The following HLT:

- Retinal embolism and thrombosis.

4 Heart Failure

SMQ Cardiac failure, narrow terms only.

5 Liver-induced MELD score ≥15

The following PT terms:

- Model for end stage liver disease score
- Model for end stage liver disease score abnormal
- Model for end stage liver disease score increased

6 Hepatic Decompensation

The following HLTs:

- Hepatic failure and associated disorders (excluding PT term cardiohepatic syndrome)
- Hepatobiliary signs and symptoms

The following PT terms:

- Gastric variceal injection
- Gastric variceal ligation
- Gastric varices haemorrhage
- Intestinal varices haemorrhage
- Oesophageal variceal injection
- Oesophageal variceal ligation
- Oesophageal varices haemorrhage
- Peritonitis bacterial

7 Drug induced liver injury

The following PT terms:

- Drug-induced liver injury
- Hepatitis toxic
- Hepatotoxicity
- Idiosyncratic drug reaction
- Paradoxical drug reaction.